Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2015

01-08-2015

Sickle cell disease is associated with iron mediated hypercoagulability

Authors: Nirmish Shah, Ian J. Welsby, Martha A. Fielder, Wayne K. Jacobsen, Vance G. Nielsen

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2015

Login to get access

Abstract

Sickle cell disease (SCD) is associated with a significant hypercoagulable state and several hemostatic anomalies have been identified in this disease state. Of interest, SCD patients can become iron overloaded after transfusion, and iron can enhance fibrinogen as a substrate for thrombin, resulting in thrombi that commence coagulation quickly and form rapidly. We hypothesized that SCD patients would display hypercoagulable plasma coagulation kinetics and an iron enhancement of coagulation. After obtaining IRB approval, we assessed coagulation kinetics and iron enhancement with viscoelastic methods in archived, citrated plasma obtained from ambulatory or hospitalized SCD patients (n = 20). All SCD patients had plasmatic hypercoagulability, and 65 % were positive for iron enhancement of coagulation. In conclusion, continuing investigation correlating such viscoelastic data with clinical symptoms may provide insight into the role played by iron in the setting of SCD, including complications such as vaso-occlusive crisis.
Literature
1.
go back to reference Pakbaz Z, Wun T (2014) Role of the hemostatic system on sickle cell disease: pathophysiology and potential therapeutics. Hematol Oncol Clin N Am 28:355–374CrossRef Pakbaz Z, Wun T (2014) Role of the hemostatic system on sickle cell disease: pathophysiology and potential therapeutics. Hematol Oncol Clin N Am 28:355–374CrossRef
2.
go back to reference Shah S, Thornburg C, Telen MJ, Ortel TL (2012) Characterization of the hypercoagulable state in patients with sickle cell disease. Thromb Res 130:e241–e245PubMedCentralPubMedCrossRef Shah S, Thornburg C, Telen MJ, Ortel TL (2012) Characterization of the hypercoagulable state in patients with sickle cell disease. Thromb Res 130:e241–e245PubMedCentralPubMedCrossRef
3.
go back to reference Porter J, Garbowski M (2013) Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program 2013:447–456PubMedCrossRef Porter J, Garbowski M (2013) Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program 2013:447–456PubMedCrossRef
4.
go back to reference Nielsen VG, Pretorius E (2014) Iron and carbon monoxide enhance coagulation and attenuate fibrinolysis by different mechanisms. Blood Coagul Fibrinolysis 25:695–702PubMedCrossRef Nielsen VG, Pretorius E (2014) Iron and carbon monoxide enhance coagulation and attenuate fibrinolysis by different mechanisms. Blood Coagul Fibrinolysis 25:695–702PubMedCrossRef
5.
go back to reference Nielsen VG, Pretorius E (2014) Iron enhanced coagulation is attenuated by chelation: a thrombelastographic and ultrastructural analysis. Blood Coagul Fibrinolysis 25:845–850PubMedCrossRef Nielsen VG, Pretorius E (2014) Iron enhanced coagulation is attenuated by chelation: a thrombelastographic and ultrastructural analysis. Blood Coagul Fibrinolysis 25:845–850PubMedCrossRef
6.
go back to reference Matika RW, Nielsen VG, Steinbrenner EB, Sussman AN, Madhrira M (2014) Hemodialysis patients have plasmatic hypercoagulability and decreased fibrinolytic vulnerability: role of carbon monoxide. ASAIO J 60:716–721PubMedCrossRef Matika RW, Nielsen VG, Steinbrenner EB, Sussman AN, Madhrira M (2014) Hemodialysis patients have plasmatic hypercoagulability and decreased fibrinolytic vulnerability: role of carbon monoxide. ASAIO J 60:716–721PubMedCrossRef
8.
go back to reference Adams RJ (2000) Lessons from the stroke prevention trial in sickle cell anemia (STOP) study. J Child Neurol 15:344–349PubMedCrossRef Adams RJ (2000) Lessons from the stroke prevention trial in sickle cell anemia (STOP) study. J Child Neurol 15:344–349PubMedCrossRef
9.
go back to reference Drasar E, Igbineweka N, Vasavda N, Free M, Awogbade M, Allman M, Mijovic A, Thein SL (2011) Blood transfusion usage among adults with sickle cell disease—a single institution experience over ten years. Br J Haematol 152:766–770PubMedCrossRef Drasar E, Igbineweka N, Vasavda N, Free M, Awogbade M, Allman M, Mijovic A, Thein SL (2011) Blood transfusion usage among adults with sickle cell disease—a single institution experience over ten years. Br J Haematol 152:766–770PubMedCrossRef
10.
go back to reference Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O (2006) Circumstances of death in adult sickle cell disease patients. Am J Hematol 81:858–863PubMedCrossRef Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O (2006) Circumstances of death in adult sickle cell disease patients. Am J Hematol 81:858–863PubMedCrossRef
12.
go back to reference Jordan L, Adams-Graves P, Kanter-Washko J, Oneal PA, Sasane M, Vekeman F, Bieri C, Magestro M, Marcellari A, Duh MS (2014) Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy. Curr Med Res Opin 31:1–11 Jordan L, Adams-Graves P, Kanter-Washko J, Oneal PA, Sasane M, Vekeman F, Bieri C, Magestro M, Marcellari A, Duh MS (2014) Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy. Curr Med Res Opin 31:1–11
Metadata
Title
Sickle cell disease is associated with iron mediated hypercoagulability
Authors
Nirmish Shah
Ian J. Welsby
Martha A. Fielder
Wayne K. Jacobsen
Vance G. Nielsen
Publication date
01-08-2015
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2015
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1230-6

Other articles of this Issue 2/2015

Journal of Thrombosis and Thrombolysis 2/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.